Biotech

Serious brain drain: When CSHL considered leaving

Cold Spring Harbor Lab officials considered moving the facility off Long Island in 1948 due to transportation concerns and the fact that local life was not very “rich.” At the time, the LIRR train from Penn Station to Syosset took 50 minutes and required a $4 taxi ride from station to lab, a “sizeable expense for a laboratory assistant to bear frequently.” Penn to Syosset today? An average 59 minutes. The transportation section of the…


Goddard Labs snags biotech honor

Goddard Labs, a Calverton-based startup that has developed breakthrough food and water testing technology, has been named Best in Show of the Mid Atlantic Bio Angels’ 1st Pitch Life Sciences competition. Although the physical prize isn’t much — a polo shirt and a press release — the bragging rights are gold plated and the connections may one day be worth even more: MABA members are active investors from Delaware to Massachusetts with deep backgrounds in…


CSHL's Bruce Stillman

CSHL plans new center to push research to market

BY JOHN L. KOMINICKI // Cold Spring Harbor Laboratory plans a $75 million therapeutic research center that would help speed to market treatments for cancer, autism and other diseases without waiting for the pharmaceutical industry to “catch up,” lab director Bruce Stillman said Tuesday. The center, which would rely on a $25 million grant from New York State and $50 million from the National Institutes of Health, would help cure a persistent problem with commercializing…


Traverse CEO Joseph Scaduto

Traverse Biosciences inks R&D, licensing deal

BY GREGORY ZELLER // Stony Brook-based startup Traverse Biosciences has inked an exclusive R&D agreement that could lead to an $8 million sublicensing option. Traverse, a resident of the Long Island High Technology Incubator at Stony Brook University, announced today that it has executed a $250,000 cooperative research and development agreement with Kansas-based Aratana Therapeutics to advance Traverse’s leading drug candidate, TRB-N0224, a potential treatment for periodontal disease in dogs and cats. Traverse Biosciences has…


Traverse CEO Joseph Scaduto

Traverse readies the move to market

BY GREGORY ZELLER // Armed with a just-executed licensing agreement for a suite of anti-inflammatory drug therapies, two-year-old Traverse Biosciences is stepping up efforts to land the investors and strategic partners necessary for rapid product development. The licensing agreement with the SUNY Research Foundation gives Traverse rights to compounds developed by Stony Brook University faculty members Lorne Golub and Francis Johnson and known as — science alert — polyenolic zinc-binding agents. Their leading drug candidate,…


DNA discoverer James Watson

Watson makes $1M CSHL gift

A million-dollar donation to Cold Spring Harbor Laboratory? Doctor Watson, we presume. And that presumption, of course, is correct: CSHL Chancellor Emeritus James Watson and his wife, Liz, have done it again, donating $1 million to support biomedical research and education at the laboratory, where Watson served as director for decades. That makes a tidy $5 million donated to CSHL, to date, by Watson, a Chicago-born molecular biologist, zoologist and geneticist who led the National…


Feinstein partnering with Australian pharma

The Feinstein Institute for Medical Research has inked a partnership deal with Novogen, an Australian pharmaceuticals giant and parent company of San Diego-based MEI Pharma, which produces a growing list of anti-cancer drugs already in the clinical stage. The collaboration is intended to develop new pharmaceutical treatments to battle brain cancers, which are currently treated by surgical removal, which traumatizes surrounding healthy brain tissue, and chemotherapy, which is limited by the brain’s natural defenses against…


Sticking it to the Man

By GREGORY ZELLER // Katarzyna Sawicka has authority issues. Not that you can really blame her. Ever since she was an undergrad at Stony Brook University, she was told her cutting-edge ideas about chemistry wouldn’t fly, that the laws governing chemistry and physics were immutable. The “authorities” – a word she uses often in place of “experts” and “the guys signing the checks” – just didn’t think she had the goods. But Sawicka was pretty…


Cold Spring Harbor Laboratory's Technology Transfer Chief Teri Willey

The Debrief: Teri Willey, Cold Spring Harbor Lab

Venture capitalization veteran Teri Willey came to Cold Spring Harbor Laboratory 18 months ago on a mission: to turn the lab’s life-altering science into bona fide business. As co-founder of seed venture fund ARCH Development Partners, VP of Technology & Business Development at Mount Sinai Medical Center and past president of the Association of University Technology Managers, among other distinguished positions, the University of Idaho graduate (with an MBA from Indiana State) had already shepherded…


CSHL's Bruce Stillman

North Shore-LIJ, CSHL in cancer partnership

Cold Spring Harbor Laboratory and North Shore-LIJ announced a joint cancer research and treatment effort that is designed to speed the region’s most-promising research to patients. The affiliation will better connect researchers at CSHL and North Shore’s Feinstein Institute for Medical Research and provide patients for clinical trials of the latest treatments, linking scieentists with more than 200 oncologists at North Shore-LIJ’s Cancer Institute. Cold Spring Harbor CEO Bruce Stillman called the paertnership a “transformative…


SBU

SBU, Cold Spring and BNL win hub grant

A $3 million grant from the National Institutes of Health will help Long Island’s three premier biotech R&D facilities speed medical breakthroughs to market. The NIH announced April 8 that it was awarding Stony Brook University’s Center for Biotechnology a three-year grant to help establish the Long Island Bioscience Hub in collaboration with Cold Spring Harbor Laboratory and Brookhaven National Laboratory in Upton. The hub will look to turn biomedical discoveries made at the three…


Bioscience Park

Lights back on, finally, at Bioscience Park

Biotech firm Codagenix, a fixture at Stony Brook’s technology incubator for the past three years, is moving to the Broad Hollow Bioscience Park at SUNY Farmingdale to qualify for the state’s Start-Up NY program. (Additional reason for the move: Robert Coleman, the Codagenix COO, is an assistant professor of biology at Farmingdale.) Codagenix uses proprietary software to genetically re-code viruses, which are then synthesized from scratch as treatment candidates – one is a promising flu…


DepYMed CEO Andreas Grill

Clinical trials for DepYMed

A joint venture between biotech stalwart Ohr Pharmaceutical and Cold Spring Harbor Laboratory is taking the fight to breast cancer – though a revolutionary treatment may still be a half-decade away at least. Cold Spring Harbor-based DepYMed, which incorporated just 10 months ago, is eyeing the first clinical trials of an enzyme inhibitor the company is proffering as a potential breakthrough for patients with HER2-positive breast cancer – a cancer that causes uncontrolled amplification in…


Ryan, former Forest veep, named to CSHL post

Cold Spring Harbor Laboratory has added another major-league bat to its commercialization lineup. Charles Ryan, former senior vice president and chief intellectual property counsel at Forest Laboratories, is CSHL’s new general counsel, bringing a wealth of experience in patent law and partnering agreements to the cutting-edge R&D facility. “I’m very excited about this opportunity,” Ryan told Innovate-LI. “Long Island is an incredible place to do science and to do business, and there’s no place on…